Priority Date: 27.12.05 (US 20050754094P)

RNAI-mediated inhibition of Rho kinase 2 for treatment of ocular hypertension / glaucoma

  • Application ID: EP13152376
  • Status: APPLICATION WITHDRAWN

Applicant

Technology company logo small
Technology Company

Attorney

no operation time available
Headquarter in Munich
active in Legal Services

Specialization

This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING). Lederer Keller Patentanwälte Partnerschaft mbB is specialized in the combination A61 and C12. We found, that TransMIT GmbH, Kailuweit & Uhlemann, Sperling Fischer & Heyner, Zacco, Vossius & Partner Patentanwälte Rechtsanwälte mbB and 183 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.

Timeline

  • 27.12.2005 - Priority Date (US 20050754094P)
  • 15.05.2013 - Publication A1 (EP2592144)

IPC Classification